Valproic Acid and Lamotrigine Differentially Modulate the Telomere Length in Epilepsy Patients

Area of Science:

• Molecular biology
• Gerontology
• Neuroscience

Background:

• Epilepsy is primarily treated with antiseizure drugs (ASDs).
• Epilepsy patients exhibit hallmarks of biological aging, including oxidative stress.
• Limited research exists on aging markers in epilepsy patients undergoing ASD treatment.

Purpose of the Study:

• To investigate the impact of ASDs on molecular aging markers, specifically telomere length (TL) and mitochondrial DNA copy number (mtDNA-CN).
• To compare aging markers in epilepsy patients with healthy controls.
• To assess the association between ASD therapy, seizure control, and aging markers.

Main Methods:

• Real-time quantitative PCR (QPCR) was used to measure TL and mtDNA-CN.
• The study included 64 epilepsy patients and 64 matched healthy controls.
• Patients were categorized by monotherapy (lamotrigine [LTG] or valproic acid [VPA]) or combination therapy (LTG + VPA).

Main Results:

• mtDNA copy number (mtDNA-CN) did not differ significantly between epilepsy patients and controls.
• Shorter TL was observed in epilepsy patients not seizure-free compared to controls, correlating with higher adverse drug reactions.
• TL varied among ASD treatment groups: VPA monotherapy showed longer TL, followed by LTG monotherapy, and then LTG + VPA combination therapy.

Conclusions:

• ASD treatment differentially modulates TL in epilepsy patients.
• TL measurement may aid clinicians in selecting optimal ASDs (VPA and/or LTG) to predict treatment response.
• Further research is warranted to explore the clinical implications of TL in epilepsy management.